Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:TTPH

Tetraphase Pharmaceuticals (TTPH) Stock Price, News & Analysis

Tetraphase Pharmaceuticals logo

About Tetraphase Pharmaceuticals Stock (NASDAQ:TTPH)

Advanced Chart

Key Stats

Today's Range
$2.18
$2.27
50-Day Range
$2.20
$2.20
52-Week Range
$0.56
$8.60
Volume
282,689 shs
Average Volume
932,542 shs
Market Capitalization
$15.98 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Receive TTPH Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Tetraphase Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

TTPH Stock News Headlines

How to Collect Up To $5,917/mo From Trump’s Made In USA Boom
How to Collect Up To $5,917/mo From Trump's Made In USA Boom Thanks to President Trump's America-First policies, a historic wave of investment is flooding back into the United States: Apple committing a colossal $500 billion to build new U.S. factories. Microsoft injecting $80 billion into domestic manufacturing. Nvidia moving critical chip production back to America. But here's the hidden opportunity: There's now a groundbreaking way for you to start collecting monthly checks from these very same companies— checks that could reach as high as $5,917 each month. Don't miss your chance to participate directly in America's industrial comeback.
TTPH_old Historical Data
10 Worst NASDAQ Biotech Stocks in the Third Quarter
See More Headlines

TTPH Stock Analysis - Frequently Asked Questions

Tetraphase Pharmaceuticals Inc (NASDAQ:TTPH) released its quarterly earnings results on Thursday, May, 7th. The biopharmaceutical company reported ($1.31) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($1.63) by $0.32. The biopharmaceutical company had revenue of $1.76 million for the quarter, compared to the consensus estimate of $2.45 million. Tetraphase Pharmaceuticals had a negative net margin of 798.18% and a negative trailing twelve-month return on equity of 210.86%.

Tetraphase Pharmaceuticals's stock reverse split before market open on Friday, September 27th 2019.The 1-20 reverse split was announced on Thursday, September 26th 2019. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, September 26th 2019. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

Based on aggregate information from My MarketBeat watchlists, some other companies that Tetraphase Pharmaceuticals investors own include Alcoa (AA), Aurinia Pharmaceuticals (AUPH), GE Aerospace (GE), Bank of America (BAC), OPKO Health (OPK), Novavax (NVAX) and Bristol Myers Squibb (BMY).

Company Calendar

Last Earnings
5/07/2020
Today
7/05/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical Preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:TTPH
Fax
N/A
Employees
119
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$70.08 million
Net Margins
-798.18%
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$7.38 million
Price / Cash Flow
N/A
Book Value
$6.68 per share
Price / Book
0.33

Miscellaneous

Free Float
N/A
Market Cap
$15.98 million
Optionable
Optionable
Beta
2.33
10 "Recession Proof" Stocks That Will Thrive in Any Market Cover

Which stocks are likely to thrive in today's challenging market? Enter your email address and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

This page (NASDAQ:TTPH) was last updated on 7/5/2025 by MarketBeat.com Staff
From Our Partners